Combining immunotherapy and targeted therapies in cancer treatment
M Vanneman, G Dranoff - Nature reviews cancer, 2012 - nature.com
During the past two decades, the paradigm for cancer treatment has evolved from relatively
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …
Cancer neoantigens and applications for immunotherapy
Recent advances in immune checkpoint blockade therapy have revolutionized the treatment
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …
[HTML][HTML] The role of DNA mismatch repair in immunotherapy of human cancer
Y He, L Zhang, R Zhou, Y Wang… - International Journal of …, 2022 - ncbi.nlm.nih.gov
DNA mismatch repair (MMR) is an important pathway which helps to maintain genomic
stability. Mutations in DNA MMR genes are found to promote cancer initiation and foster …
stability. Mutations in DNA MMR genes are found to promote cancer initiation and foster …
Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines
Due to advances in sequencing technology, somatically mutated cancer antigens, or
neoantigens, are now readily identifiable and have become compelling targets for …
neoantigens, are now readily identifiable and have become compelling targets for …
The BCR‐ABL1 transcript type influences response and outcome in P hiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with …
F Castagnetti, G Gugliotta, M Breccia… - American journal of …, 2017 - Wiley Online Library
The most frequent BCR‐ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the
e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the …
e13a2 (b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the …
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia
M Bleakley, SR Riddell - Immunology and cell biology, 2011 - Wiley Online Library
Minor histocompatibility (H) antigens are major targets of a graft‐versus‐leukemia (GVL)
effect mediated by donor CD8+ and CD4+ T cells following allogeneic hematopoietic cell …
effect mediated by donor CD8+ and CD4+ T cells following allogeneic hematopoietic cell …
Novel therapeutic approaches in chronic myeloid leukemia
NÖ Yurttaş, AE Eşkazan - Leukemia Research, 2020 - Elsevier
The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …
myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment …
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
M Massimino, S Stella, E Tirrò, C Romano, MS Pennisi… - Molecular cancer, 2018 - Springer
The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …
Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation
H Mu, X Zhu, H Jia, L Zhou, H Liu - Frontiers in Oncology, 2021 - frontiersin.org
Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …
leukemia (CML), patients are not cured with the current therapy modalities. Also, the more …
SYT‐SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the J apanese M usculoskeletal O ncology G roup
S Kawaguchi, T Tsukahara, K Ida, S Kimura… - Cancer …, 2012 - Wiley Online Library
In the present study, we evaluated the safety and effectiveness of SYT‐SSX‐derived peptide
vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT …
vaccines in patients with advanced synovial sarcoma. A 9‐mer peptide spanning the SYT …